DGX:NYSEQuest Diagnostics Incorporated Analysis

Quest Diagnostics (DGX) sits at $200.9, comfortably above its 20‑day SMA of 206.2 but still trailing the 50‑day SMA of 191.9, indicating a bullish medium‑term trend despite a near‑neutral RSI of 49.9. The MACD histogram is negative and the signal line is bearish, while volume has been decreasing, suggesting short‑term pressure near the identified support at $191.9. The stock trades at a forward PE of 17.5, below the industry average of 25.2, yet the DCF‑derived fair value of $115.7 signals a substantial premium. Revenue grew 7.1% YoY to $11.0 B, with operating margins of 13.97% and a solid ROE of 14.8%, supporting the growth narrative. Dividend yield sits at 1.71% with a 36% payout ratio and a recent 7.5% increase, underscoring dividend sustainability. Debt‑to‑equity is high at 90%, but ample operating cash flow ($1.89 B) and free cash flow ($1.01 B) mitigate liquidity concerns. The beta of 0.22 (computed) and a 30‑day volatility of 28.8% point to low market sensitivity but moderate price swings.
Overall, the company combines defensive healthcare exposure, consistent dividend growth, and respectable earnings momentum, but the current market price appears stretched relative to intrinsic valuation. Investor sentiment is buoyed by “Extreme Greed” on the fear‑greed index, while the technical picture remains mixed, suggesting a cautious stance until price aligns closer to support or valuation benchmarks.